Recent Updates
Recently added Catalysts
OKYO Positive Sentiment Score: 75/100

OKYO Pharma Announces Purchase of Shares by Chairman

Tuesday, July 21, 2026 1 min read
Key Takeaway: OKYO Pharma Limited announced that its Chairman, Gabriele Cerrone, has purchased 25,000 ordinary shares at $1.40 each, increasing his total holdings to 20.51% of the company's issued share capital. This move indicates Cerrone's confidence in the company's prospects. OKYO is also set to begin a Phase 3 clinical trial for its treatment of neuropathic corneal pain later this year.
Price reaction · baseline $1.37 (2026-07-20 close) · hit pre-market · 1 other OKYO headline(s) in the window, move may be shared
day 0 close · peak
+5.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Chairman Gabriele Cerrone is increasing his stake in the company.
  • The purchase reflects confidence in OKYO Pharma's future.
  • OKYO is preparing to initiate a Phase 3 clinical trial.

Full Press Release Details

LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that its Chairman, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 25,000 ordinary shares at $1.40 per share, bringing his total holding to 10,851,416 ordinary shares, which is 20.51% of issued share capital.

About OKYOPharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.
For further information, please visitwww.okyopharma.com.

For further inquiries:

OKYO Pharma LtdPaul SpencerBusiness Development and Investor Relations+44 (0) 207 495 2379Email:info@okyopharma.com

Frequently Asked Questions

Who is the Chairman of OKYO Pharma?

The Chairman of OKYO Pharma is Gabriele Cerrone.

How many shares did Gabriele Cerrone purchase?

Gabriele Cerrone purchased 25,000 ordinary shares.

What percentage of shares does Cerrone now hold?

Cerrone now holds 20.51% of the issued share capital.

What is OKYO Pharma developing?

OKYO Pharma is developing therapies for neuropathic corneal pain and eye diseases.

When will OKYO start its Phase 3 trial?

OKYO plans to initiate its Phase 3 trial in the second half of this year.

Tags: OKYO Viatris Investor Conferences Healthcare OKYO Pharma Gabriele Cerrone share purchase neuropathic corneal pain Phase 3 trial
Last updated: Jul 21, 2026